Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma
Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma
复制标题
DOI：
10.1006/gyno.2000.5984
复制
发表时间：
2000-12-01
影响因子：
4.7
通讯作者：
Morgan, M
中科院分区：
文献类型：
--
作者：
Hoffman, MA;Blessing, JA;Morgan, M
目标。本研究的目的有两个：（1）评估 CI-958 对可测量的铂耐药性卵巢癌患者的抗肿瘤功效； (2)确定CI-958对这些患者的毒性性质和程度。方法。患者每 3 周静脉注射 CI-958 560 mg/m(2)，每一到两个周期进行一次肿瘤测量。结果。在 25 例复发性铂耐药性疾病患者中，1 例出现部分缓解 (PR)，6 例患者病情稳定 (SD)。结论。在测试的剂量和时间表下，CI-958 对铂耐药卵巢癌的活性极小，(C) 2000 学术出版社。
Objectives. The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients.Methods. Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles.Results. In 25 cases with recurrent platinum-resistant disease, there was one partial response (PR) and six patients had stable disease (SD).Conclusions. CI-958 has minimal activity in platinum-resistant ovarian cancer at the dose and schedule tested, (C) 2000 Academic Press.